Secnidazole

Identification

Name
Secnidazole
Accession Number
DB12834
Description

Secnidazole is a second-generation 5-nitroimidazole antimicrobial that is structurally related to other 5-nitroimidazoles including Metronidazole and Tinidazole, but displays improved oral absorption and longer terminal elimination half-life than antimicrobial agents in this class 1. Secnidazole is selective against many anaerobic Gram-positive and Gram-negative bacteria and protozoa. In September 2017, FDA granted approval to secnidazole under the market name Solosec as a single-dose oral treatment for bacterial vaginosis, which is a common vaginal infection in women aged 15 to 44 years. The antimicrobial therapy is only intended to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria Label.

Type
Small Molecule
Groups
Approved
Structure
Thumb
Weight
Average: 185.183
Monoisotopic: 185.080041226
Chemical Formula
C7H11N3O3
Synonyms
  • 1-(2­ hydroxypropyl)-2-methyl-5-nitroimidazole
  • 1-(2-methyl-5-nitro-1H-imidazol-1-yl) propan-2­ ol
  • Secnidazole
External IDs
  • PM-185184
  • RP 14539
  • RP-14539
  • SYM-1219

Pharmacology

Indication

Indicated for the treatment of bacterial vaginosis in adult women .

Associated Conditions
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics

Secnidazole is a nitroimidazole antimicrobial drug that displays selectivity against many anaerobic Gram-positive and Gram-negative bacteria and protozoa 1. In vitro studies demonstrates the effectiveness of the drug against Bacteroides fragilis, Trichomonas vaginalis, Entamoeba histolytica and Giardia lamblia 1. There is no significant bacterial or protozoal resistance reported from secnidazole treatment 1.

Mechanism of action

Secnidazole enters the bacterial cell as a prodrug without an antimicrobial activity. The drug is converted to an active form via reduction of nitro groups to radical anions by bacterial enzymes. The radical anions are thought to interfere with bacterial DNA synthesis of susceptible isolates Label.

Absorption

Secnidazole is rapidly and completely absorbed after oral administration 1. Following a single oral dose of 2 g in healthy adult female subjects, the mean (SD) secnidazole peak plasma concentration (Cmax) of 45.4 (7.64) mcg/mL and mean (SD) systemic exposure (AUC0-inf) of 1331.6 (230.16) mcg x hr/mL was reached. Median (range) time to peak concentration (Tmax) was 4.0 (3.0-4.0) hours Label.

Volume of distribution

The apparent volume of distribution of secnidazole is approximately 42-49 L Label,1.

Protein binding

The plasma protein binding of secnidazole is < 5-15% Label,1.

Metabolism

According to in vitro studies, secnidazole is metabolized via oxidation by human hepatic CYP450 enzyme system with ≤ 1% conversion to metabolites Label.

Route of elimination

The predominant route of elimination is renal elimination. Following a single oral dose of 2g secnidazole, approximately 15% of the drug is excreted as unchanged compoung in the urine Label.

Half-life

The plasma elimination half-life for secnidazole is approximately 17 hours Label.

Clearance

The total body clearance of secnidazole is approximately 25 mL/min. The renal clearance of secnidazole is approximately 3.9 mL/min Label.

Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity

Oral LD50 in mouse, rabbit and rat is 300 mg/kg, 3200 mg/kg and 980 mg/kg, in a respective order MSDS. Secnidazole was positive in the Bacterial Reverse Mutation Assay, but was negative for the rat micronucleus test and mouse lymphoma test. No parental toxicity or signs of reproductive toxicity were observed in female rat fertility studies at doses of up to the maximum tolerated dose of 300 mg/kg/day Label.

Affected organisms
  • Trichomonas vaginalis, Giardia duodenalis, and Entamoeba histolytica
  • Bacteria and protozoa
  • Bacteroides fragilis
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
  • Take with or without food. Sprinkle onto applesauce, yogurt, or pudding and ingest without crushing the granules.

Products

Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
SolosecGranule2 g/4.8gOralRopack Inc.2018-03-01Not applicableUS flag
SolosecGranule2 g/4.8gOralSymbiomix Therapeutics2017-09-292017-10-30US flag
SolosecGranule2 g/4.8gOralLupin Pharmaceuticals, Inc.2017-10-30Not applicableUS flag
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more

Categories

ATC Codes
P01AB07 — SecnidazoleJ01RA07 — Azithromycin, fluconazole and secnidazole
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as nitroimidazoles. These are compounds containing an imidazole ring which bears a nitro group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Azoles
Sub Class
Imidazoles
Direct Parent
Nitroimidazoles
Alternative Parents
Nitroaromatic compounds / 1,2,5-trisubstituted imidazoles / N-substituted imidazoles / Heteroaromatic compounds / Secondary alcohols / Propargyl-type 1,3-dipolar organic compounds / Organic oxoazanium compounds / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds
show 3 more
Substituents
1,2,5-trisubstituted-imidazole / Alcohol / Allyl-type 1,3-dipolar organic compound / Aromatic heteromonocyclic compound / Azacycle / C-nitro compound / Heteroaromatic compound / Hydrocarbon derivative / N-substituted imidazole / Nitroaromatic compound
show 14 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Chemical Identifiers

UNII
R3459K699K
CAS number
3366-95-8
InChI Key
KPQZUUQMTUIKBP-UHFFFAOYSA-N
InChI
InChI=1S/C7H11N3O3/c1-5(11)4-9-6(2)8-3-7(9)10(12)13/h3,5,11H,4H2,1-2H3
IUPAC Name
1-(2-methyl-5-nitro-1H-imidazol-1-yl)propan-2-ol
SMILES
CC(O)CN1C(C)=NC=C1N(=O)=O

References

General References
  1. Gillis JC, Wiseman LR: Secnidazole. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic use in the management of protozoal infections and bacterial vaginosis. Drugs. 1996 Apr;51(4):621-38. [PubMed:8706597]
  2. INVIMA Product Information: Bioprox (itraconazole/secnidazole) oral tablets [Link]
PubChem Compound
71815
PubChem Substance
347829000
ChemSpider
64839
BindingDB
50349330
RxNav
36314
ChEBI
94433
ChEMBL
CHEMBL498847
Wikipedia
Secnidazole
FDA label
Download (344 KB)
MSDS
Download (78.8 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4RecruitingTreatmentBacterial Vaginoses1
3CompletedTreatmentBacterial Vaginosis (BV)2
3CompletedTreatmentTrichomonas Infections1
3CompletedTreatmentVaginal Discharge1
3TerminatedTreatmentDiverticular Sigmoïditis1
2CompletedTreatmentBacterial Vaginosis (BV)1
1, 2CompletedBasic ScienceCholera / Salmonella Typhi Infection1
Not AvailableCompletedTreatmentGiardiasis1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Capsule, coatedOral154.66 mg
Powder, for suspensionOral2.7778 g
TabletOral1000 mg
Tablet, coatedOral133.33 mg
Tablet, film coatedOral500 mg
Tablet, coated500 mg
Tablet, coatedOral75 mg
Tablet, film coatedOral75 mg
TabletOral37.5 mg
Tablet, coatedOral500 mg
Tablet, coatedOral1 g
TabletOral75 mg
Tablet, coatedOral1000 mg
Tablet, coatedOral37.5 mg
Powder, for suspensionOral3.333 g
Powder, for suspensionOral3 g
Powder, for suspensionOral0.75 g
Tablet, film coatedOral1 g
TabletOral500 mg
Tablet, film coated1000 mg
Tablet, film coated500 mg
GranuleOral2 g
GranuleOral2 g/4.8g
Capsule, coatedOral33.33 mg
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)Region
US10335390No2019-07-022035-09-04US flag
US10682338No2015-09-042035-09-04US flag
Additional Data Available
  • Filed On
    Filed On

    The date on which a patent was filed with the relevant government.

    Learn more

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility4.88 mg/mLALOGPS
logP0.25ALOGPS
logP-0.043ChemAxon
logS-1.6ALOGPS
pKa (Strongest Acidic)15.16ChemAxon
pKa (Strongest Basic)3.08ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area83.87 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity45.64 m3·mol-1ChemAxon
Polarizability17.57 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-004r-0900000000-4607b9260ff959d777e0
MS/MS Spectrum - , positiveLC-MS/MSsplash10-004i-3900000000-b3c36444a446482a04bc

Drug created on October 20, 2016 18:36 / Updated on September 16, 2020 15:10

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates